Gastric cancer cells-derived exosomal miR-151a-5p induces an immunosuppressive microenvironment through promoting LAG3TAMs infiltration.
0/5 보강
APA
Zhou P, Qu H, et al. (2026). Gastric cancer cells-derived exosomal miR-151a-5p induces an immunosuppressive microenvironment through promoting LAG3TAMs infiltration.. Journal of experimental & clinical cancer research : CR. https://doi.org/10.1186/s13046-026-03703-9
MLA
Zhou P, et al.. "Gastric cancer cells-derived exosomal miR-151a-5p induces an immunosuppressive microenvironment through promoting LAG3TAMs infiltration.." Journal of experimental & clinical cancer research : CR, 2026.
PMID
41923099 ↗
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (5)
- Advances in isolation and detection technologies and immunotherapy applications of circulating tumor cells (Review).
- Efficacy of PD-1 inhibitor plus induction chemotherapy for nasopharyngeal carcinoma with high-grade extranodal extension: a multicenter retrospective analysis.
- Beta-sitosterol-baicalein-guanosine synergistically alleviates Warburg effect in colorectal cancer via EGFR/ERK pathway.
- Schott-Derived Exosome-Like Nanovesicles Promote Apoptosis in Colorectal Cancer by Regulating the Lysosome-Mediated Mitophagy Pathway.
- Role of tumor microenvironment in regulator of tumor progression and immunotherapy.
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- Advances in Targeted Therapy for Human Epidermal Growth Factor Receptor 2-Low Tumors: From Trastuzumab to Antibody-Drug Conjugates.
- Unleashing CAR-T potential in solid tumors: overcoming intrinsic and extrinsic hurdles to improve therapy.
- Novel roles of SETD2 in tumor metabolism and immunotherapy: a systematic review and meta-analysis.
- Negative trial but positive lesson: reframing immunotherapy resistance from one-size-fits-all to precision strategies.
- SLC2A1 tumour-associated macrophages spatially control CD8 T cell function and drive resistance to immunotherapy in non-small-cell lung cancer.
- Chalcone-containing dual-targeting PD-L1/tubulin small molecules: a novel approach for cancer immunotherapy.